Año: 2022
Journal Impact Factor (JIF): 16.80
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
IMMUNOLOGY | SCIE | 7/161 | Q1 | T1 | D1 |
Año: 2022
Journal Citation Indicator (JCI): 1,440
Categoría | Posición | Cuartil | Tercil | Decil | Percentil |
---|---|---|---|---|---|
IMMUNOLOGY | 25/177 | Q1 | T1 | D2 | 86,16 |
Año:
2022
CiteScore:
27,900
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Immunology | 9/217 | Q1 | T1 | D1 |
Immunology and Allergy | 8/211 | Q1 | T1 | D1 |
SJR año:
2022
Factor de Impacto:
4,689
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Immunology | 10/236 | Q1 | T1 | D1 |
Immunology and Allergy | 8/226 | Q1 | T1 | D1 |
Agencia | Código de Proyecto |
---|---|
Department of Radiation Oncology at WeillCornell Medicine | - |
Functional Genomics Initiative | - |
Lytix Biopharma | - |
Mantle Cell Lymphoma Research Initiative grant from the Leukemia and Lymphoma Society | - |
Phosplatin | - |
Stand Up to Cancer | ZP-6177 |
US Department of Defense (DoD) Breast Cancer Research Program (BRCP) | BC180476P1 |
# | Autor | Afiliación |
---|---|---|
1 | Jiménez-Cortegana, Carlos | Universidad de Sevilla; Hospital Universitario Virgen Macarena; Weill Cornell Medicine (United States) |
2 | Galassi, Claudia | Weill Cornell Medicine (United States) |
3 | Weill Cornell Medicine; Caryl and Israel Englander Institute for Precision Medicine (United States) |